Over the past decade, Alta Partners has built a strong and diversified portfolio. Alta has invested in over 180 companies, including some of the leaders in the biopharmaceuticals, medical technology, and information technology sectors.
San Mateo, CA
Allakos is a privately held, product-focused biotechnology company developing first-in-class antibody-based therapeutics to treat diseases in which dysregulation of the Th2 response plays a key role in pathology, including allergic disease, inflammation and diseases characterized by excess production of inflammatory cells. Allakos has generated a preclinical pipeline of novel antibodies targeting cell types implicated in allergic and inflammatory responses which it intends to advance to clinical proof-of-concept. Headquartered in the San Francisco Bay Area, Allakos is led by a management team with broad experience in antibody research and development and a strong advisory board of experts in the areas of disease focus.
|Applied Genetic Technologies Corporation|
Applied Genetic Technologies Corporation is a gene therapy company focused on curing genetic defects that cause blindness and other systemic disorders. The Company is developing a pipeline of products that utilize its proprietary, adeno-associated virus (AAV) delivery system and herpes-helper virus production technology.
Durham, North Carolina
Headquartered in Durham, N.C., Bioventus is Smith & Nephew’s former Biologics Division/Clinical Therapies business that generates about 250 million dollars in revenue annually on a worldwide basis. The product line includes the EXOGEN® Ultrasound Bone Healing System, and hyaluronic acid joint fluid therapy products, SUPARTZ® and DUROLANE®, which treat the symptoms of osteoarthritis. These innovative products provide clinical benefits to patients and cost savings to payers by delaying or eliminating the need for knee surgery. In the case of bone stimulation, expensive follow-on procedures for bone fractures which do not heal are avoided.
Contact: Guy P. Nohra
San Diego, CA
Lumena Pharmaceuticals is a privately-held biotechnology company developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease.
Zafgen is developing first in class drugs to treat obesity and related co-morbidities. The Company’s lead program, Beloranib is in Phase II clinical trials.
|ZS Pharma, Inc.|
ZS Pharma is a late-stage company developing a drug to treat Hyperkalemia. Hyperkalemia is a serious and potentially life-threating condition where one’s potassium levels become dangerously elevated causing arrhythmias and cardiac arrest. Hyperkalemia is most often seen in patients with chronic kidney disease (CKD) due to renal insufficiency and the condition is exacerbated by medications that these patients typically take (i.e. they increase serum potassium). In the U.S. alone there are approximately 25 million people with CKD and this number is expected to increase for the foreseeable future.
Contact: Guy P. Nohra